Detailed Coverage

Metropolis Healthcare FY26 Results

Metropolis Healthcare's FY26 revenue reached ₹1,646 crore, a 23.6% year-on-year increase. Profit After Tax (PAT) grew by 31% to ₹191 crore.

Reader Takeaway: Strong organic growth exceeds guidance, but competition and supply chain risks need monitoring.

What just happened

Metropolis Healthcare announced its financial results for the fiscal year 2025-26. The company reported consolidated revenue of ₹1,646 crore, a significant jump of 23.6% compared to the previous year. Profit After Tax (PAT) also saw a substantial increase of 31%, reaching ₹191 crore. The company highlighted strong organic performance, with revenue at ₹1,510 crore and EBITDA at ₹392 crore, achieving organic revenue growth of 13.7%, surpassing its initial guidance of 12-13%.

Why this matters

The results indicate Metropolis Healthcare's successful transition into an integration phase following its expansion efforts. Beating organic growth targets is a positive sign for investors, suggesting efficient execution. The company's strategic shift towards integrating acquired entities and focusing on its 'One Metropolis' initiative is expected to drive future revenue growth and margin expansion.

The backstory

In March 2026, Metropolis Healthcare issued bonus shares in a 3:1 ratio. This corporate action signaled management's confidence in the company's financial health and commitment to shareholder value. The company has been actively integrating its acquisitions, including Core Diagnostics, Scientific Pathology, DAPIC, and Ambika Pathology, under unified systems.

What changes now

Metropolis Healthcare is now prioritizing integration over aggressive expansion. The 'One Metropolis' initiative aims to streamline operations, quality, technology, and culture across its expanded network. The company has set a medium-term revenue growth target of 14-15% annually and anticipates a 125-150 basis point margin improvement in FY27, targeting a sustainable EBITDA margin of 27-28%.

Risks to watch

Investors should be aware of increasing competition in the routine diagnostics market from hospital-based labs and digital platforms, which could affect test pricing and margins. Additionally, the company's dependence on imported reagents and consumables poses a risk due to potential supply chain disruptions and currency fluctuations.

Peer comparison

While specific peer data was not provided in the filing, Metropolis Healthcare's organic revenue growth of 13.7% for FY26 exceeded its guided range. The company aims for a medium-term growth of 14-15%, positioning it for continued expansion within the diagnostic sector.

Context metrics (time-bound)

• FY26 Revenue: ₹1,646 crore (+23.6% YoY)
• FY26 PAT: ₹191 crore (+31% YoY)
• FY26 Organic Revenue: ₹1,510 crore (+13.7% YoY, beat guidance)
• FY26 EBITDA: ₹401 crore (Margin: 24.4%)
• Network: Crossed 5,000+ touchpoints in over 750 towns.
• TruHealth (Preventive): Grew 21%, now 19% of total revenue.
• Digital Business: Generates 1.6x higher revenue per patient.
• Target FY27 EBITDA Margin: 27-28%

What to track next

Investors should monitor the execution of the 'One Metropolis' integration strategy, the company's ability to achieve its targeted margin improvement in FY27, and the sustained growth of its preventive (TruHealth) and specialty diagnostics segments.